Skip to results

Keyword or reference number

Area of interest

Type

Showing 1 to 10 of 22

Guidance and quality standards awaiting development
TitleType
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [TSID12177]Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [TSID12146]Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]Technology appraisal guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidance
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]Technology appraisal guidance
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Technology appraisal guidance
Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477]Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All